Bausch Health Cos — Key Risks
Massive Debt Load Creates Constant Risk of Financial Distress
As of December 31, 2025, Bausch Health carries $20.2 billion in total debt, with $4.2 billion maturing in 2028 and $4.1 billion due in 2030. Servicing this debt requires generating substantial cash every year, and if the company underperforms its forecasts, it could breach financial maintenance covenants in its credit agreements — potentially triggering debt acceleration and, in a worst case, bankruptcy or liquidation.
Xifaxan Generic Competition Could Devastate Revenue Overnight
Xifaxan (rifaximin) represents a "substantial amount" of the company's total revenue, yet generic competitors could enter the market as early as January 2028 — or even earlier if a rival launches "at-risk" before patent litigation is fully resolved. On top of that, the U.S. government has already negotiated a lower Medicare price for Xifaxan effective January 1, 2027 under the Inflation Reduction Act. A sudden loss of exclusivity on a single product this important could cause revenue to collapse rapidly.
The Bausch + Lomb Separation May Never Happen — Or May Happen Badly
The company has been trying to fully spin off its Bausch + Lomb eye health subsidiary, but the process faces legal challenges, tax complications, regulatory hurdles, and market uncertainty. The separation could be delayed, restructured, or abandoned entirely. Meanwhile, the effort is consuming significant management time and money regardless of outcome, and a failed separation could disappoint investors who have priced in its completion.
A Critical Pipeline Failure Signals Deep Research Risk
In January 2026, the company's Phase 3 clinical trial for amorphous-rifaximin SSD (a next-generation liver disease treatment known as the RED-C program) failed to meet its primary endpoints. This single setback is expected to trigger a $1.4 billion goodwill impairment charge in Q1 2026. It illustrates how dependent the company's valuation is on pipeline products that may never reach market.
Pricing Power Is Structurally Constrained
The company has voluntarily committed to limiting price increases through its Patient Access and Pricing Team, and now faces government-imposed constraints as well. When prices cannot be raised, the company loses "price appreciation credits" from wholesalers that offset distribution fees — a direct hit to margins. Combined with IRA-driven Medicare price negotiations, this creates a multi-front squeeze on revenue.
A Legacy of Legal Trouble Continues to Drain Resources
Bausch Health still faces multiple securities litigations related to past accounting and disclosure practices, including its former relationship with specialty pharmacy Philidor. These cases consume management attention and legal budget regardless of outcome, and any adverse ruling could result in material fines, penalties, or business practice changes — potentially pushing the company into covenant violations on its debt.
Key Management Instability Since the Bausch + Lomb IPO
Since the B+L IPO, the company has replaced its CEO, CFO (twice, including an interim), General Counsel, and other key executives. Frequent leadership turnover disrupts strategy execution, unsettles employees and business partners, and makes it harder to attract top talent given the company's reputational challenges — all at a moment when navigating debt obligations and the separation demands exceptional management continuity.